Pharmaceutical News

RSS

Researchers discover first broad spectrum drug that can potently kill aging cells in culture

Researchers from the University of Arkansas for Medical Sciences and other institutions are reporting the discovery of the first broad spectrum drug that can potently kill senescent (or aging) cells in culture and effectively clear the cells in animals by specifically targeting a pathway that is critical for the survival of senescent cells.

15 Dec 2015

Flu vaccine strategy needs to be reworked, York U study finds

In the face of a flu epidemic, a one-size fits all vaccine strategy won't be effective, a York University study has found. Instead, strategies need to change significantly depending on the characteristics of each region in Canada and how easily the particular flu strain spreads.

15 Dec 2015

Global Health Impact Index can measure actual impact of drugs worldwide

Billions of dollars have been spent on developing drugs and supplying them around the world, but which companies' drugs are actually making an impact? The Global Health Impact Index, headed by Binghamton University Associate Professor Nicole Hassoun and highlighted in a new article published Friday in PLOS ONE, addresses this issue by ranking pharmaceutical companies based on their drugs' impact on global health.

15 Dec 2015

VistaPharm announces launch of Potassium Chloride Solution

VistaPharm today announced that it has launched Potassium Chloride Solution, USP, 10% in Unit Dose. The product is supplied to the market in a 50 count case of 30mL unit dose cups.

14 Dec 2015

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Validus Pharmaceuticals LLC, together with Wood Creek Capital Management, LLC ("Wood Creek"), announced today the acquisition of the U.S. rights to several well-known product lines from Sanofi US: Anzemet (dolasetron mesylate) Injection and Tablets, Claforan (cefotaxime) Injection/IM/IV, Demerol (meperidine hydrochloride) Tablets, Drisdol (ergocalciferol) Capsules and Oral Solution, Hiprex (methenamine hippurate) Tablets, Lasix (furosemide) Tablets, Norpramin (desipramine hydrochloride) Tablets and Trental (pentoxifylline) Tablets.

14 Dec 2015

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix NV, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies, for the treatment of cancer and severe autoimmune diseases, announces that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease.

14 Dec 2015

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

CTI BioPharma Corp. today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX (arsenic trioxide).

14 Dec 2015

Study offers insight into how female Viagra affects the brain

As the drug touted as "the female Viagra" comes to market, researchers at the University of Wisconsin-Madison are learning more about how the drug, called flibanserin, affects the brain.

13 Dec 2015

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

12 Dec 2015

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection.

11 Dec 2015

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

Cardiorentis AG, a privately held biopharmaceutical company, today announced that the U.S. Food and Drug Administration has granted Fast Track status to Ularitide, an investigational therapy for the treatment of acute decompensated heart failure (ADHF).

11 Dec 2015

Findings may lead to new treatment strategy for phobia

A new study published in the latest issue of Biological Psychiatry reports the successful and instant reduction of fear in spider-fearful participants following a 2-minute exposure combined with a single dose of a regular pharmacological treatment.

11 Dec 2015

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

11 Dec 2015

Study: Spanish-speaking Hispanic women less likely to use neuraxial analgesia during labor

Why do Hispanic women have reduced rates of epidural or spinal (neuraxial) analgesia during labor? Language barriers may be a key factor, according to a study in Anesthesia & Analgesia.

11 Dec 2015

TSRI-led study shows how different drugs regulate protein linked to asthma, obesity and diabetes

A new study, led by scientists at The Scripps Research Institute, shows how different pharmaceutical drugs hit either the "on" or "off" switch of a signaling protein linked to asthma, obesity and type 2 diabetes.

11 Dec 2015

New guidelines may help reduce medication use among seniors

We're not getting any younger. According to the Administration for Community Living, by 2060, there will be about 98 million older persons in the United States — more than twice their number in 2013.

11 Dec 2015

Single dose of psilocybin decreases anxiety, depression in cancer patients

A single dose of psilocybin, the major hallucinogenic component in magic mushrooms, induces long-lasting decreases in anxiety and depression in patients diagnosed with life-threatening cancer according to a new study presented today at the annual meeting of the American College of Neuropsychopharmacology.

11 Dec 2015

LSD reduces connectivity within human brain networks

LSD is known to cause changes in consciousness, including "ego-dissolution", or a loss of the sense of self. Despite a detailed knowledge of the action of LSD at specific serotonin receptors, it has not been understood how this these pharmacological effects can translate into such a profound effect on consciousness.

11 Dec 2015

Pharmaceutical News

Researchers discover first broad spectrum drug that can potently kill aging cells in culture

Flu vaccine strategy needs to be reworked, York U study finds

Global Health Impact Index can measure actual impact of drugs worldwide

VistaPharm announces launch of Potassium Chloride Solution

Validus, Wood Creek announce acquisition of U.S. rights to several Sanofi US products

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

CTI BioPharma earns $10 million milestone payment from Teva for TRISENOX (arsenic trioxide)

Study offers insight into how female Viagra affects the brain

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

FDA approves Teligent's sNDA for CEFOTAN (cefotetan) for Injection

FDA grants Fast Track status to Cardiorentis' Ularitide for treatment of ADHF

Findings may lead to new treatment strategy for phobia

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

Study: Spanish-speaking Hispanic women less likely to use neuraxial analgesia during labor

TSRI-led study shows how different drugs regulate protein linked to asthma, obesity and diabetes

New guidelines may help reduce medication use among seniors

Single dose of psilocybin decreases anxiety, depression in cancer patients

LSD reduces connectivity within human brain networks

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News